RE: Hi guys25 Apr 2020 11:05
I honestly don’t think there is much point in trying to score points between NCYT and AVCT. There is plenty of room for both to do well. This new virus isn’t just going to disappear, it’s here to stay now. You could imagine a world where, say, health care professionals, educators, police, etc, public sector workers who have face to face contact with the public, all need rock solid testing maybe annually. And a need for quick tests for any large public gatherings.
What does seem to be demonstrably the case is that NCYT is much further along the monetisation curve, in having a proven product which is already being manufactured and shipped. If you consider the relative positions and then look at market caps, I think right now NCYT is the more undervalued.